Search

Your search keyword '"Rimini, Margherita"' showing total 280 results
Start Over Author "Rimini, Margherita"
280 results on '"Rimini, Margherita"'

1. Genomic profiling of small bowel adenocarcinoma: a pooled analysis from 3 databases

Author

Aparicio, Thomas, Henriques, Julie, Svrcek, Magali, Zaanan, Aziz, Manfredi, Sylvain, Casadei-Gardini, Andrea, Tougeron, David, Gornet, Jean-Marc, Jary, Marine, Terrebonne, Eric, Piessen, Guillaume, Afchain, Pauline, Lecaille, Cédric, Pocard, Marc, Lecomte, Thierry, Rimini, Margherita, Di Fiore, Frédéric, Le Brun Ly, Valérie, Cascinu, Stefano, Vernerey, Dewi, and Laurent Puig, Pierre

Published
2024
Full Text
View/download PDF

2. Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab

Author

Persano, Mara, Rimini, Margherita, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Rossari, Federico, Yoo, Changhoon, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Masi, Gianluca, Bergamo, Francesca, Amadeo, Elisabeth, Vitiello, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Iavarone, Massimo Alberto, Cabibbo, Giuseppe, Montes, Margarida, Foschi, Francesco Giuseppe, Vivaldi, Caterina, Soldà, Caterina, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Bruccoleri, Mariangela, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Hiraoka, Atsushi, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Foti, Silvia, Camera, Silvia, Piscaglia, Fabio, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2024
Full Text
View/download PDF

3. Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab

Author

Rimini, Margherita, Montes, Margarida, Amadeo, Elisabeth, Vitiello, Francesco, Kudo, Masatoshi, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Lonardi, Sara, Finkelmeier, Fabian, Salani, Francesca, Antonuzzo, Lorenzo, Marra, Fabio, Iavarone, Massimo, Cabibbo, Giuseppe, Foschi, Francesco Giuseppe, Silletta, Marianna, Sacco, Rodolfo, Rapposelli, Ilario Giovanni, Scartozzi, Mario, Nicoletta, Pella, Aldrighetti, Luca, Persano, Mara, Camera, Silvia, Rossari, Federico, Foti, Silvia, Kumada, Takashi, Hiraoka, Atsushi, Iwamoto, Hideki, Rizzato, Mario Domenico, Himmelsbach, Vera, Masi, Gianluca, Corradi, Mattia, Celsa, Ciro, Fabio, Conti, Frassineti, Giovanni Luca, Cascinu, Stefano, Casadei-Gardini, Andrea, and Presa, Jose

Published
2024
Full Text
View/download PDF

4. Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study

Author

Rimini, Margherita, Masi, Gianluca, Lonardi, Sara, Nichetti, Federico, Pressiani, Tiziana, Lavacchi, Daniele, Jessica, Lucchetti, Giordano, Guido, Scartozzi, Mario, Tamburini, Emiliano, Pastorino, Alessandro, Rapposelli, Ilario Giovanni, Daniele, Bruno, Martinelli, Erika, Garajova, Ingrid, Aprile, Giuseppe, Schirripa, Marta, Formica, Vincenzo, Salani, Francesca, Winchler, Costanza, Bergamo, Francesca, Balsano, Rita, Gusmaroli, Eleonora, Lorenzo, Angotti, Landriscina, Matteo, Pretta, Andrea, Toma, Ilaria, Pirrone, Chiara, Diana, Anna, Leone, Francesco, Brunetti, Oronzo, Brandi, Giovanni, Garattini, Silvio Ken, Satolli, Maria Antonietta, Rossari, Federico, Fornaro, Lorenzo, Niger, Monica, Zanuso, Valentina, De Rosa, Antonio, Ratti, Francesca, Aldrighetti, Luca, De Braud, Filippo, Foti, Silvia, Rizzato, Mario Domenico, Vivaldi, Caterina, Stefano, Cascinu, Rimassa, Lorenza, Antonuzzo, Lorenzo, and Casadei-Gardini, Andrea

Published
2024
Full Text
View/download PDF

5. Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab

Author

Rimini, Margherita, Loi, Eleonora, Rizzato, Mario Domenico, Pressiani, Tiziana, Vivaldi, Caterina, Gusmaroli, Eleonora, Antonuzzo, Lorenzo, Martinelli, Erika, Garajova, Ingrid, Giordano, Guido, Lucchetti, Jessica, Schirripa, Marta, Cornara, Noemi, Rossari, Federico, Vitiello, Francesco, Amadeo, Elisabeth, Persano, Mara, Piva, Vittoria Matilde, Balsano, Rita, Salani, Francesca, Pircher, Chiara, Cascinu, Stefano, Niger, Monica, Fornaro, Lorenzo, Rimassa, Lorenza, Lonardi, Sara, Scartozzi, Mario, Zavattari, Patrizia, and Casadei-Gardini, Andrea

Published
2024
Full Text
View/download PDF

6. Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma

Author

Camera, Silvia, Rimini, Margherita, Rossari, Federico, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Yoo, Changhoon, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Masi, Gianluca, Bergamo, Francesca, Salani, Francesca, Marseglia, Mariarosaria, Amadeo, Elisabeth, Vitiello, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Iavarone, Massimo, Cabibbo, Giuseppe, Montes, Margarida, Foschi, Francesco Giuseppe, Vivaldi, Caterina, Lonardi, Sara, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Hiraoka, Atsushi, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Persano, Mara, Foti, Silvia, Piscaglia, Fabio, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2024
Full Text
View/download PDF

7. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population

Author

Rimini, Margherita, Fornaro, Lorenzo, Rizzato, Mario Domenico, Antonuzzo, Lorenzo, Rossari, Federico, Satake, Tomoyuki, Vandeputte, Hanne, Vivaldi, Caterina, Pressiani, Tiziana, Lucchetti, Jessica, Kim, Jin Won, Abidoye, Oluseyi, Rapposelli, Ilario Giovanni, Tamberi, Stefano, Finkelmeier, Fabian, Giordano, Guido, Nichetti, Federico, Chon, Hong Jae, Braconi, Chiara, Pirrone, Chiara, Castet, Florian, Tamburini, Emiliano, Yoo, Changhoon, Parisi, Alessandro, Diana, Anna, Scartozzi, Mario, Prager, Gerald W., Avallone, Antonio, Schirripa, Marta, Kim, Il Hwan, Perkhofer, Lukas, Oneda, Ester, Verrico, Monica, Adeva, Jorge, Chan, Stephen L., Spinelli, Gian Paolo, Personeni, Nicola, Garajova, Ingrid, Rodriquenz, Maria Grazia, Leo, Silvana, Salani, Francesca, De Rosa, Antonio, Lavacchi, Daniele, Foti, Silvia, Ikeda, Masafumi, Dekervel, Jeroen, Niger, Monica, Balsano, Rita, Tonini, Giuseppe, Kang, Minsu, Bekaii-Saab, Tanios, Esposito, Luca, Boccaccino, Alessandra, Himmelsbach, Vera, Landriscina, Matteo, Djaballah, Selma Ahcene, Zanuso, Valentina, Masi, Gianluca, Lonardi, Sara, Rimassa, Lorenza, and Casadei-Gardini, Andrea

Published
2024
Full Text
View/download PDF

9. Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients

Author

Rimini, Margherita, Persano, Mara, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Salani, Francesca, Lonardi, Sara, Piscaglia, Fabio, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Schirripa, Marta, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Hiraoka, Atsushi, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Burgio, Valentina, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2023
Full Text
View/download PDF

10. Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study

Author

Persano, Mara, Rimini, Margherita, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Rimassa, Lorenza, Presa, José, Masi, Gianluca, Yoo, Changhoon, Lonardi, Sara, Tovoli, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Pressiani, Tiziana, Kawaguchi, Takumi, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Piscaglia, Fabio, Hiraoka, Atsushi, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Iavarone, Massimo, Di Costanzo, Giovanni, Marra, Fabio, Scartozzi, Mario, Tamburini, Emiliano, Cabibbo, Giuseppe, Foschi, Francesco Giuseppe, Silletta, Marianna, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Cammarota, Antonella, Burgio, Valentina, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2023
Full Text
View/download PDF

11. Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies

Author

Parisi, Alessandro, Delaunay, Blandine, Pinterpe, Giada, Hollebecque, Antoine, Blanc, Jean Frederic, Bouattour, Mohamed, Assenat, Eric, Ben Abdelghani, Meher, Sarabi, Matthieu, Niger, Monica, Vivaldi, Caterina, Mandalà, Mario, Palloni, Andrea, Bensi, Maria, Garattini, Silvio Ken, Tougeron, David, Combe, Pierre, Salati, Massimiliano, Rimini, Margherita, Cella, Chiara Alessandra, Tucci, Marco, Diana, Anna, Mori, Elena, Longarini, Raffaella, Artru, Pascal, Roth, Gael, Evesque, Ludovic, Vienne, Agathe, Turpin, Anthony, Hiret, Sandrine, Bourgeois, Vincent, Herve, Camille, Paulon, Rodolphe, Stacoffe, Marion, Malka, David, Neuzillet, Cindy, Edeline, Julien, Lievre, Astrid, Guimbaud, Rosine, Chapda, Marie Christelle Pajiep, Rimassa, Lorenza, Giampieri, Riccardo, Valle, Juan, Berardi, Rossana, and Fares, Nadim

Published
2024
Full Text
View/download PDF

12. Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?

Author

Rimini, Margherita, Persano, Mara, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Masi, Gianluca, Yoo, Changhoon, Lonardi, Sara, Piscaglia, Fabio, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Pressiani, Tiziana, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Hiraoka, Atsushi, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Burgio, Valentina, Rimassa, Lorenza, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2023
Full Text
View/download PDF

13. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study

Author

Allende, Daniela S, Amaddeo, Giuliana, Argemi, Josepmaria, Baulande, Sylvain, Beaufrère, Aurélie, Bermúdez-Ramos, María, Boulagnon-Rombi, Camille, Boursier, Jérôme, Bruges, Léa, Calderaro, Julien, Campani, Claudia, Caruso, Stefano, Casadei-Gardini, Andrea, Castano Garcia, Andres, Chan, Stephen Lam, D'Alessio, Antonio, Di Tommaso, Luca, Diaz, Alba, Digklia, Antonia, Dufour, Jean-François, Garcia-Porrero, Guillermo, Ghaffari Laleh, Narmin, Gnemmi, Viviane, Gopal, Purva, Graham, Rondell P., Heurgué, Alexandra, Iavarone, Massimo, Iñarrairaegui, Mercedes, Kather, Jakob Nikolas, Klein, Christophe, Labgaa, Ismail, Lameiras, Sonia, Legoix, Patricia, Lequoy, Marie, Leung, Howard Ho-Wai, Loménie, Nicolas, Maggioni, Marco, Maille, Pascale, Marín-Zuluaga, Juan Ignacio, Mendoza-Pacas, Guillermo, Michalak, Sophie, Mínguez, Beatriz, El Nahhas, Omar S M, Nault, Jean-Charles, Navale, Pooja, Ningarhari, Massih, Paradis, Valérie, Park, Young Nyun, Pawlotsky, Jean-Michel, Pedica, Federica, Perbellini, Riccardo, Peter, Simon, Pinato, David James, Pinter, Matthias, Radu, Pompilia, Regnault, Hélène, Reig, Maria, Rela, Mohamed, Rhee, Hyungjin, Rimassa, Lorenza, Rimini, Margherita, Salcedo, María Teresa, Sangro, Bruno, Scheiner, Bernhard, Sempoux, Christine, Su, Tung-Hung, Torres, Callie, Tran, Nguyen H, Trépo, Eric, Varela, Maria, Verset, Gontran, Vij, Mukul, Vogel, Arndt, Wendum, Dominique, Zeng, Qinghe, and Ziol, Marianne

Published
2023
Full Text
View/download PDF

16. Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients

Author

Rimini, Margherita, Fabregat-Franco, Carles, Persano, Mara, Burgio, Valentina, Bergamo, Francesca, Niger, Monica, Scartozzi, Mario, Rapposelli, Ilario Giovanni, Aprile, Giuseppe, Ratti, Francesca, Pedica, Federica, Verdaguer, Helena, Rizzato, Mario, Nichetti, Federico, Lai, Eleonora, Cappetta, Alessandro, Macarulla, Teresa, Fassan, Matteo, De Braud, Filippo, Pretta, Andrea, Simionato, Francesca, De Cobelli, Francesco, Aldrighetti, Luca, Fornaro, Lorenzo, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2023
Full Text
View/download PDF

17. Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients

Author

Persano, Mara, Rimini, Margherita, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Masi, Gianluca, Yoo, Changhoon, Lonardi, Sara, Tovoli, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Niizeki, Takashi, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Stefanini, Bernardo, Hiraoka, Atsushi, Sho, Takuya, Nishida, Naoshi, Steup, Christoph, Iavarone, Massimo, Di Costanzo, Giovanni, Marra, Fabio, Tamburini, Emiliano, Cabibbo, Giuseppe, Foschi, Francesco Giuseppe, Silletta, Marianna, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Campani, Claudia, Amadeo, Elisabeth, Rossari, Federico, Burgio, Valentina, Cascinu, Stefano, Scartozzi, Mario, and Casadei-Gardini, Andrea

Published
2023
Full Text
View/download PDF

18. Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis

Author

Rimini, Margherita, Burgio, Valentina, Antonuzzo, Lorenzo, Rimassa, Lorenza, Oneda, Ester, Lavacchi, Daniele, Personeni, Nicola, Ratti, Francesca, Pedica, Federica, Della Corte, Angelo, Persano, Mara, De Cobelli, Francesco, Aldrighetti, Luca, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2022
Full Text
View/download PDF

19. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

Author

Casadei-Gardini, Andrea, Rimini, Margherita, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Rimassa, Lorenza, Presa, José, Masi, Gianluca, Yoo, Changhoon, Lonardi, Sara, Tovoli, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Pressiani, Tiziana, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Piscaglia, Fabio, Hiraoka, Atsushi, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Iavarone, Massimo, Di Costanzo, Giovanni, Marra, Fabio, Scartozzi, Mario, Tamburini, Emiliano, Cabibbo, Giuseppe, Foschi, Francesco Giuseppe, Silletta, Marianna, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Burgio, Valentina, Persano, Mara, Della Corte, Angelo, Ratti, Francesca, De Cobelli, Francesco, Aldrighetti, Luca, Cascinu, Stefano, and Cucchetti, Alessandro

Published
2023
Full Text
View/download PDF

20. THU-446 VETC predicts benefit of anti-angiogenic drugs in advanced HCC

Author

De Carlo, Camilla, primary, Akpinar, Reha, additional, Durante, Barbara, additional, Pirozzi, Angelo, additional, Renne, Salvatore, additional, Pressiani, Tiziana, additional, Calderaro, Julien, additional, Zanuso, Valentina, additional, Ng, Irene Oi-Lin, additional, Cheung, Tanto, additional, Eccher, Albino, additional, Sighinolfi, Pamela, additional, Villa, Erica, additional, Iavarone, Massimo, additional, Maggioni, Marco, additional, Shao, Yu-Yun, additional, Lonardi, Sara, additional, Rizzato, Mario Domenico, additional, De Rosa, Antonio, additional, Fassan, Matteo, additional, Angerilli, Valentina, additional, Pedica, Federica, additional, Rimini, Margherita, additional, Giardini, Andrea Casadei, additional, Santoro, Armando, additional, Park, Young Nyun, additional, Roncalli, Massimo, additional, Terracciano, Luigi, additional, Piscuoglio, Salvatore, additional, Rimassa, Lorenza, additional, and Tommaso, Luca Di, additional

Published
2024
Full Text
View/download PDF

21. The Prognostic Role of Baseline Eosinophils in HPV-Related Cancers: a Multi-institutional Analysis of Anal SCC and OPC Patients Treated with Radical CT-RT

Author

Rimini, Margherita, Franco, Pierfrancesco, Bertolini, Federica, Berardino, De Bari, giulia, Zampino Maria, Stefano, Vegge, Andrikou, Kalliopi, Arcadipane, Francesca, Napolitano, Martina, Buno, Lavajo Vieira, Alessandra, Gerardi Marianna, Olivero, Francesco, Ferreri, Filippo, Ricardi, Umberto, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2022
Full Text
View/download PDF

22. Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma

Author

Rimini, Margherita, Fabregat-Franco, Carles, Burgio, Valentina, Lonardi, Sara, Niger, Monica, Scartozzi, Mario, Rapposelli, Ilario Giovanni, Aprile, Giuseppe, Ratti, Francesca, Pedica, Federica, Verdaguer, Helena, Rizzato, Mario, Nichetti, Federico, Lai, Eleonora, Cappetta, Alessandro, Macarulla, Teresa, Fassan, Matteo, De Braud, Filippo, Pretta, Andrea, Simionato, Francesca, De Cobelli, Francesco, Aldrighetti, Luca, Fornaro, Lorenzo, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2022
Full Text
View/download PDF

23. Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience

Author

Bardasi, Camilla, Spallanzani, Andrea, Benatti, Stefania, Spada, Francesca, Laffi, Alice, Antonuzzo, Lorenzo, Lavacchi, Daniele, Marconcini, Riccardo, Ferrari, Marco, Rimini, Margherita, Caputo, Francesco, Santini, Chiara, Cerma, Krisida, Casadei-Gardini, Andrea, Andrikou, Kalliopi, Salati, Massimiliano, Bertolini, Federica, Fontana, Annalisa, Dominici, Massimo, Luppi, Gabriele, and Gelsomino, Fabio

Published
2021
Full Text
View/download PDF

24. Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis

Author

Casadei-Gardini, Andrea, Rimassa, Lorenza, Rimini, Margherita, Yoo, Changhoon, Ryoo, Baek-Yeol, Lonardi, Sara, Masi, Gianluca, Kim, Hyung-Don, Vivaldi, Caterina, Ryu, Min-Hee, Rizzato, Mario Domenico, Salani, Francesca, Bang, Yeonghak, Pellino, Antonio, Catanese, Silvia, Burgio, Valentina, Cascinu, Stefano, and Cucchetti, Alessandro

Published
2021
Full Text
View/download PDF

25. Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a real-world, multicenter study

Author

Rossari, Federico, primary, Tada, Toshifumi, additional, Suda, Goki, additional, Shimose, Shigeo, additional, Kudo, Masatoshi, additional, Yoo, Changhoon, additional, Cheon, Jaekyung, additional, Finkelmeier, Fabian, additional, Lim, Ho Yeong, additional, Presa, José, additional, Masi, Gianluca, additional, Bergamo, Francesca, additional, Amadeo, Elisabeth, additional, Vitiello, Francesco, additional, Kumada, Takashi, additional, Sakamoto, Naoya, additional, Iwamoto, Hideki, additional, Aoki, Tomoko, additional, Chon, Hong Jae, additional, Himmelsbach, Vera, additional, Iavarone, Massimo, additional, Cabibbo, Giuseppe, additional, Montes, Margarida, additional, Foschi, Francesco Giuseppe, additional, Vivaldi, Caterina, additional, Soldà, Caterina, additional, Sho, Takuya, additional, Niizeki, Takashi, additional, Nishida, Naoshi, additional, Steup, Christoph, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Tani, Joji, additional, Atsukawa, Masanori, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Tsuji, Kunihiko, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Ogawa, Chikara, additional, Nishimura, Takashi, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Shimada, Noritomo, additional, Kawata, Kazuhito, additional, Hiraoka, Atsushi, additional, Tada, Fujimasa, additional, Ohama, Hideko, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Imai, Michitaka, additional, Kosaka, Hisashi, additional, Naganuma, Atsushi, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Kaibori, Masaaki, additional, Iijima, Hiroko, additional, Hiasa, Yoichi, additional, Persano, Mara, additional, Foti, Silvia, additional, Camera, Silvia, additional, Stefanini, Bernardo, additional, Scartozzi, Mario, additional, Cascinu, Stefano, additional, Casadei-Gardini, Andrea, additional, and Rimini, Margherita, additional

Published
2024
Full Text
View/download PDF

26. Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience

Author

Rimini, Margherita, Yoo, Changhoon, Lonardi, Sara, Masi, Gianluca, Granito, Alessandro, Bang, Yeonghak, Rizzato, Mario Domenico, Vivaldi, Caterina, Ielasi, Luca, Kim, Hyung-Don, Bergamo, Francesca, Salani, Francesca, Leoni, Simona, Ryoo, Baek-Yeol, Ryoo, Min-Hee, Burgio, Valentina, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2021
Full Text
View/download PDF

28. Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis

Author

Bang, Yeonghak, Yoo, Changhoon, Lonardi, Sara, Kim, Hyung-Don, Vivaldi, Caterina, Rimini, Margherita, Frassineti, Giovanni Luca, Park, Sook Ryun, Rizzato, Mario Domenico, Ryu, Min-Hee, Salani, Francesca, Rapposelli, Ilario Giovanni, Ryoo, Baek-Yeol, Zagonel, Vittorina, Massa, Valentina, Valgiusti, Martina, Burgio, Valentina, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2021
Full Text
View/download PDF

29. Durvalumab Plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: A Large Real-Life Worldwide Population

Author

Rimini, Margherita, primary, Fornaro, Lorenzo, additional, Rizzato, Mario, additional, Antonuzzo, Lorenzo, additional, Rossari, Federico, additional, Satake, Tomoyuki, additional, Vandeputte, Hanne, additional, Vivaldi, Caterina, additional, Pressiani, Tiziana, additional, Lucchetti, Jessica, additional, Kim, Jin Won, additional, Abidoye, Oluseyi, additional, Rapposelli, Ilario Giovanni, additional, Tamberi, Stefano, additional, Finkelmeier, Fabian, additional, Giordano, Guido, additional, Nichetti, Federico, additional, Chon, Hong Jae, additional, Braconi, Chiara, additional, Pirrone, Chiara, additional, Castet, Florian, additional, Tamburini, Emiliano, additional, Yoo, Changhoon, additional, Parisi, Alessandro, additional, Diana, Anna, additional, Scartozzi, Mario, additional, Prager, Gerald, additional, Avallone, Antonio, additional, Schirripa, Marta, additional, Kim, Il Hwan, additional, Perkhofer, Lukas, additional, Oneda, Ester, additional, Verrico, Monica, additional, Adeva, Jorge, additional, Chan, Stephen L., additional, Spinelli, Gian Paolo, additional, Personeni, Nicola, additional, Garajova, Ingrid, additional, Rodriquenz, Maria Grazia, additional, Leo, Silvana, additional, Salani, Francesca, additional, De Rosa, Antonio, additional, Lavacchi, Daniele, additional, Foti, Silvia, additional, Ikeda, Masafumi, additional, Dekervel, Jeroen, additional, Niger, Monica, additional, Balsano, Rita, additional, Tonini, Giuseppe, additional, Kang, Minsu, additional, Bekaii-Saab, Tanios, additional, Esposito, Luca, additional, Boccaccino, Alessandra, additional, Himmelsbach, Vera, additional, Landriscina, Matteo, additional, Djaballah, Selma Ahcene, additional, Zanuso, Valentina, additional, Masi, Gianluca, additional, Lonardi, Sara, additional, Rimassa, Lorenza, additional, and Casadei Gardini, Andrea, additional

Published
2024
Full Text
View/download PDF

30. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study

Author

Zeng, Qinghe, primary, Klein, Christophe, additional, Caruso, Stefano, additional, Maille, Pascale, additional, Allende, Daniela S, additional, Mínguez, Beatriz, additional, Iavarone, Massimo, additional, Ningarhari, Massih, additional, Casadei-Gardini, Andrea, additional, Pedica, Federica, additional, Rimini, Margherita, additional, Perbellini, Riccardo, additional, Boulagnon-Rombi, Camille, additional, Heurgué, Alexandra, additional, Maggioni, Marco, additional, Rela, Mohamed, additional, Vij, Mukul, additional, Baulande, Sylvain, additional, Legoix, Patricia, additional, Lameiras, Sonia, additional, Amaddeo, Giuliana, additional, Argemi, Josepmaria, additional, Beaufrère, Aurélie, additional, Bermúdez-Ramos, María, additional, Boursier, Jérôme, additional, Bruges, Léa, additional, Calderaro, Julien, additional, Campani, Claudia, additional, Castano Garcia, Andres, additional, Chan, Stephen Lam, additional, D'Alessio, Antonio, additional, Di Tommaso, Luca, additional, Diaz, Alba, additional, Digklia, Antonia, additional, Dufour, Jean-François, additional, Garcia-Porrero, Guillermo, additional, Ghaffari Laleh, Narmin, additional, Gnemmi, Viviane, additional, Gopal, Purva, additional, Graham, Rondell P., additional, Iñarrairaegui, Mercedes, additional, Kather, Jakob Nikolas, additional, Labgaa, Ismail, additional, Lequoy, Marie, additional, Leung, Howard Ho-Wai, additional, Loménie, Nicolas, additional, Marín-Zuluaga, Juan Ignacio, additional, Mendoza-Pacas, Guillermo, additional, Michalak, Sophie, additional, El Nahhas, Omar S M, additional, Nault, Jean-Charles, additional, Navale, Pooja, additional, Paradis, Valérie, additional, Park, Young Nyun, additional, Pawlotsky, Jean-Michel, additional, Peter, Simon, additional, Pinato, David James, additional, Pinter, Matthias, additional, Radu, Pompilia, additional, Regnault, Hélène, additional, Reig, Maria, additional, Rhee, Hyungjin, additional, Rimassa, Lorenza, additional, Salcedo, María Teresa, additional, Sangro, Bruno, additional, Scheiner, Bernhard, additional, Sempoux, Christine, additional, Su, Tung-Hung, additional, Torres, Callie, additional, Tran, Nguyen H, additional, Trépo, Eric, additional, Varela, Maria, additional, Verset, Gontran, additional, Vogel, Arndt, additional, Wendum, Dominique, additional, Zeng, Qinghe, additional, and Ziol, Marianne, additional

Published
2023
Full Text
View/download PDF

31. Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents

Author

Amadeo, Elisabeth, Foti, Silvia, Camera, Silvia, Rossari, Federico, Persano, Mara, Lo Prinzi, Federica, Vitiello, Francesco, Casadei-Gardini, Andrea, and Rimini, Margherita

Abstract

ABSTRACTIntroductionHepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the first for primary liver tumors. In recent years greater therapeutic advancement was represented by employment of tyrosine kinase inhibitors (TKIs) either in monotherapy or in combination with immune checkpoint inhibitors (ICIs).Areas coveredMajor attention was given to target therapies in the last couple of years, especially in those currently under phase II trials. Priority was given either to combinations of novel ICI and TKIs or those targeting alternative mutations of major carcinogenic pathways.Expert opinionAs TKIs are playing a more crucial role in HCC therapeutic strategies, it is fundamental to further expand molecular testing and monitoring of acquired resistances. Despite the recent advancement in both laboratory and clinical studies, further research is necessary to face the discrepancy in clinical practice.

Published
2024
Full Text
View/download PDF

32. Treatment options for advanced hepatocellular carcinoma: the potential of biologics

Author

Rossari, Federico, Foti, Silvia, Camera, Silvia, Persano, Mara, Casadei-Gardini, Andrea, and Rimini, Margherita

Abstract

ABSTRACTIntroductionAdvanced hepatocellular carcinoma (HCC) represents a significant global health burden, whose treatment has been recently revolutionized by the advent of biologic treatments. Despite that, innovative therapeutic regimens and approaches, especially immune-based, remain to be explored aiming at extending the therapeutic benefits to a wider population of patients.Areas coveredThis review comprehensively discusses the evolving landscape of biological treatment modalities for advanced HCC, including immune checkpoint inhibitors, antiangiogenic monoclonal antibodies, tumor-targeting monoclonal antibodies either naked or drug-conjugated, therapeutic vaccines, oncolytic viruses, adoptive cell therapies, and cytokine-based therapies. Key clinical trials and preclinical studies are examined, highlighting the actual or potential impact of these interventions in reshaping treatment paradigms for HCC.Expert opinionTailored and rational combination strategies, leveraging the synergistic effects of different modalities, represent a promising approach to maximize treatment efficacy in advanced HCC, which should aim at conversion endpoints to increase the fraction of patients eligible for curative approaches. The identification of predictive biomarkers holds the key to optimizing patient selection and improving therapeutic outcomes.

Published
2024
Full Text
View/download PDF

33. Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab.

Author

Rimini, Margherita, Stefanini, Bernardo, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Finkelmeier, Fabian, Yoo, Changhoon, Presa, José, Amadeo, Elisabeth, genovesi, Virginia, De Grandis, Maria Caterina, Iavarone, Massimo, Marra, Fabio, Foschi, Francesco, Tamburini, Emiliano, Rossari, Federico, Vitiello, Francesco, Bartalini, Linda, and Soldà, Caterina

Subjects
*BODY mass index, *ATEZOLIZUMAB, *BEVACIZUMAB, *PROGNOSIS, *UNIVARIATE analysis
Abstract

Introduction: Overweight is a negative prognostic factor in the general population in the long term. However, the role of body mass index (BMI) in the short‐mid term in advanced tumours is unclear. The present analysis investigates the role of BMI weight classes in a large sample of patients affected by HCC and receiving atezolizumab plus bevacizumab or lenvatinib as first‐line treatment. Methods and Material: The cohort included consecutive patients affected by BCLC‐c and BCLC‐B HCC patients from a multicenter international study group who received atezolizumab plus bevacizumab or lenvatinib as first‐line therapy. Population was stratified according to the BMI in under‐, over‐ and normal‐weight according to the conventional thresholds. The primary objective of the study was to evaluate the prognostic and predictive impact of BMI in patients affected by advanced or intermediate HCC. Survival curves were estimated using the product‐limit method of Kaplan–Meier. The role of stratification factors was analysed with log‐rank tests. Results: 1292 consecutive patients with HCC were analysed. 466 (36%) patients were treated with lenvatinib and 826 (64%) patients were treated with atezolizumab plus bevacizumab. In the atezolizumab plus bevacizumab arm, 510 (62%) patients were normal‐weight, 52 (6%) underweight and 264 (32%) overweight. At the univariate analysis for OS, underweight patients had significantly shorter OS compared to normal‐weight patients, whereas no differences were found between normal‐weight versus overweight. Multivariate analysis confirmed that underweight patients had significantly shorter OS compared to normal‐weight patients (HR: 1.7; 95% CI: 1.0–2.8; p =.0323). In the lenvatinib arm, 26 patients (5.6%) were categorized as underweight, 256 (54.9%) as normal‐weight, and 184 (39.5%) as overweight. At the univariate analysis for OS, no significant differences were found between normal‐weight versus underweight and between normal‐weight versus overweight, which was confirmed at multivariate analysis. Conclusion: Our analysis highlighted a prognostic role of BMI in a cohort of patients with advanced HCC who received atezolizumab plus bevacizumab, while no prognostic role for low BMI was apparent in patients who received lenvatinib. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art.

Author

Rimini, Margherita, Presi, Silvia, Pipitone, Giovanni Battista, Russo Raucci, Annalisa, Ratti, Francesca, Della Corte, Angelo, Pedica, Federica, Vanella, Giuseppe, Tonon, Giovanni, Burgio, Valentina, Vitiello, Francesco, Rossari, Federico, Amadeo, Elisabeth, Maria Giulia, Cangi, Pecciarini, Lorenza, Arcidiacono, Paolo Giorgio, Falcinelli, Francesca, Cascinu, Stefano, De Cobelli, Francesco, and Aldrighetti, Luca

Subjects
BILIARY tract cancer, HEREDITARY cancer syndromes, GENETIC counseling, HEREDITARY nonpolyposis colorectal cancer, GENETIC testing, GERM cells, DNA mismatch repair
Abstract

A genetic predisposition seems to be involved in biliary tract cancer, but the prevalence of germline mutations in BTC remains unclear, and the therapeutic role of the germline pathologic variants is still unknown. The aim of the present work is to systematically review the data available on the hereditary predisposition of biliary tract cancer by a specific research on PubMed, in order to highlight the most important critical points and to define the current possible role of germinal testing and genetic counseling in this setting of patients. Basing on data already available, we decided to start in our institution a specific genetic protocol focused on biliary tract cancer patients, which includes genetic counseling and, if indicated, germline test. The inclusion criteria are: 1) Patient with personal history of oncologic disease other than BTC, 2) Patient with familiar history of oncologic disease (considering relatives of first and second grade), 3) Patient with ≤ 50 years old, 4) Patient presenting a somatic mutation in genes involved in DNA damage repair pathways and mismatch repair. The aim of the presented protocol is to identify germline pathogenic variants with prophylactic and therapeutic impact, and to collect and integrate a significant amount of clinical, familial, somatic, and genetic data. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib.

Author

Iavarone, Massimo, Alimenti, Eleonora, Tada, Toshifumi, Shimose, Shigeo, Suda, Goki, Yoo, Changhoon, Soldà, Caterina, Piscaglia, Fabio, Tosetti, Giulia, Marra, Fabio, Vivaldi, Caterina, Conti, Fabio, Schirripa, Marta, Iwamoto, Hideki, Sho, Takuya, Lee, So Heun, Rizzato, Mario Domenico, Tonnini, Matteo, Rimini, Margherita, and Campani, Claudia

Subjects
HEPATOCELLULAR carcinoma, PORTAL vein, ESOPHAGEAL varices, HEMORRHAGE, ODDS ratio, CONFIDENCE intervals
Abstract

Introduction: Lenvatinib is indicated for the forefront treatment of advanced hepatocellular carcinoma (aHCC), but its use may be limited by the risk of esophagogastric varices (EGV) bleeding. This study assessed the prevalence, predictors, and complications of EGV in aHCC patients treated with lenvatinib. Methods: In this multicenter international retrospective study, cirrhotic patients treated with lenvatinib for aHCC, were enrolled if upper-gastrointestinal endoscopy was available within 6 months before treatment. Primary endpoint was the incidence of EGV bleeding during lenvatinib therapy; secondary endpoints were predictors for EGV bleeding, prevalence, and risk factors for the presence of EGV and high-risk EGV at baseline, as well as impact of EGV bleeding on patients' survival. Results: 535 patients were enrolled in the study (median age: 72 years, 78% male, 63% viral etiology, 89% Child-Pugh A, 16% neoplastic portal vein thrombosis [nPVT], 56% Barcelona Clinic Liver Cancer-C): 234 had EGV (44%), 70 (30%) were at high risk and 59 were on primary prophylaxis. During lenvatinib treatment, 17 patients bled from EGV (3 grade 5), the 12-month cumulative incidence being 3%. The only baseline independent predictor of EGV bleeding was the presence of baseline high-risk EGV (hazard ratio: 6.94, 95% confidence interval [CI]: 2.23–21.57, p = 0.001). In these patients the 12-month risk was 17%. High-risk varices were independently associated with Child-Pugh B score (odds ratio [OR]: 2.12; 95% CI: 1.08–4.17, p = 0.03), nPVT (OR: 2.54; 95% CI: 1.40–4.61, p = 0.002), and platelets <150,000/μL (OR: 2.47; 95% CI: 1.35–4.50, p = 0.003). Conclusion: In hepatocellular carcinoma patients treated with lenvatinib, the risk of EGV bleeding was mostly low but significant only in patients with high-risk EGV at baseline. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. α‐FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma

Author

Rossari, Federico, primary, Tada, Toshifumi, additional, Suda, Goki, additional, Shimose, Shigeo, additional, Kudo, Masatoshi, additional, Yoo, Changhoon, additional, Cheon, Jaekyung, additional, Finkelmeier, Fabian, additional, Lim, Ho Yeong, additional, Presa, José, additional, Masi, Gianluca, additional, Bergamo, Francesca, additional, Amadeo, Elisabeth, additional, Vitiello, Francesco, additional, Kumada, Takashi, additional, Sakamoto, Naoya, additional, Iwamoto, Hideki, additional, Aoki, Tomoko, additional, Chon, Hong Jae, additional, Himmelsbach, Vera, additional, Iavarone, Massimo, additional, Cabibbo, Giuseppe, additional, Montes, Margarida, additional, Foschi, Francesco Giuseppe, additional, Vivaldi, Caterina, additional, Soldà, Caterina, additional, Sho, Takuya, additional, Niizeki, Takashi, additional, Nishida, Naoshi, additional, Steup, Christoph, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Tani, Joji, additional, Atsukawa, Masanori, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Tsuji, Kunihiko, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Ogawa, Chikara, additional, Nishimura, Takashi, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Shimada, Noritomo, additional, Kawata, Kazuhito, additional, Hiraoka, Atsushi, additional, Tada, Fujimasa, additional, Ohama, Hideko, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Imai, Michitaka, additional, Kosaka, Hisashi, additional, Naganuma, Atsushi, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Kaibori, Masaki, additional, Iijima, Hiroko, additional, Hiasa, Yoichi, additional, Persano, Mara, additional, Burgio, Valentina, additional, Piscaglia, Fabio, additional, Scartozzi, Mario, additional, Cascinu, Stefano, additional, Casadei‐Gardini, Andrea, additional, and Rimini, Margherita, additional

Published
2023
Full Text
View/download PDF

37. Incidence and predictors of esophagogastric varices bleeding in patients with hepatocellular carcinoma in lenvatinib

Author

Iavarone, Massimo, primary, Alimenti, Eleonora, additional, Tada, Toshifumi, additional, Shimose, Shigeo, additional, Suda, Goki, additional, Yoo, Changhoon, additional, Soldà, Caterina, additional, Piscaglia, Fabio, additional, Tosetti, Giulia, additional, Marra, Fabio, additional, Vivaldi, Caterina, additional, Conti, Fabio, additional, Schirripa, Marta, additional, Iwamoto, Hideki, additional, Sho, Takuya, additional, Lee, So Heun, additional, Rizzato, Mario Domenico, additional, Tonnini, Matteo, additional, Rimini, Margherita, additional, Campani, Claudia, additional, Masi, Gianluca, additional, Foschi, Francesco, additional, Bruccoleri, Mariangela, additional, Kawaguchi, Takumi, additional, Kumada, Takashi, additional, Hiraoka, Atsushi, additional, Atsukawa, Masanori, additional, Fukunishi, Shinya, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Kawata, Kazuhito, additional, Tada, Fujimasa, additional, Ohama, Hideko, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Arai, Taeang, additional, Imai, Michitaka, additional, Naganuma, Atsushi, additional, Casadei-Gardini, Andrea, additional, and Lampertico, Pietro, additional

Published
2023
Full Text
View/download PDF

40. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data

Author

Rimini, Margherita, primary, Fornaro, Lorenzo, additional, Lonardi, Sara, additional, Niger, Monica, additional, Lavacchi, Daniele, additional, Pressiani, Tiziana, additional, Lucchetti, Jessica, additional, Giordano, Guido, additional, Pretta, Andrea, additional, Tamburini, Emiliano, additional, Pirrone, Chiara, additional, Rapposelli, Ilario Giovanni, additional, Diana, Anna, additional, Martinelli, Erika, additional, Garajová, Ingrid, additional, Simionato, Francesca, additional, Schirripa, Marta, additional, Formica, Vincenzo, additional, Vivaldi, Caterina, additional, Caliman, Enrico, additional, Rizzato, Mario Domenico, additional, Zanuso, Valentina, additional, Nichetti, Federico, additional, Angotti, Lorenzo, additional, Landriscina, Matteo, additional, Scartozzi, Mario, additional, Ramundo, Matteo, additional, Pastorino, Alessandro, additional, Daniele, Bruno, additional, Cornara, Noemi, additional, Persano, Mara, additional, Gusmaroli, Eleonora, additional, Cerantola, Riccardo, additional, Salani, Francesca, additional, Ratti, Francesca, additional, Aldrighetti, Luca, additional, Cascinu, Stefano, additional, Rimassa, Lorenza, additional, Antonuzzo, Lorenzo, additional, and Casadei‐Gardini, Andrea, additional

Published
2023
Full Text
View/download PDF

42. Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments

Author

Persano, Mara, primary, Rimini, Margherita, additional, Tada, Toshifumi, additional, Suda, Goki, additional, Shigeo, Shimose, additional, Kudo, Masatoshi, additional, Cheon, Jaekyung, additional, Finkelmeier, Fabian, additional, Presa, José, additional, Masi, Gianluca, additional, Yoo, Changhoon, additional, Lonardi, Sara, additional, Piscaglia, Fabio, additional, Iavarone, Massimo, additional, Di Costanzo, Giuseppe, additional, Marra, Fabio, additional, Cabibbo, Giuseppe, additional, Foschi, Francesco, additional, Siletta, Marianna, additional, Cascinu, Stefano, additional, Scartozzi, Mario, additional, and Gardini, Andrea Casadei, additional

Published
2023
Full Text
View/download PDF

43. Deep learning predicts sensitivity to atezolizumab-bevacizumab from digital slides of hepatocellular carcinoma

Author

Zeng, Qinghe, primary, Klein, Christophe, additional, Caruso, Stefano, additional, Maille, Pascale, additional, Allende, Daniela, additional, Minguez, Beatriz, additional, Iavarone, Massimo, additional, Ningarhari, Massih, additional, Gardini, Andrea Casadei, additional, Pedica, Federica, additional, Rimini, Margherita, additional, perbellini, Riccardo, additional, Boulagnon-Rombi, Camille, additional, Heurgue-berlot, Alexandra, additional, Maggioni, Marco, additional, Rela, Mohd., additional, Vij, Mukul, additional, Baulande, Sylvain, additional, Legoix, Patricia, additional, Lameiras, Sonia, additional, Labgaa, Ismail, additional, Sempoux, Christine, additional, Digkilia, Antonia, additional, Ghaffari-Laleh, Narmin, additional, Kather, Jakob Nikolas, additional, El Nahhas, Omar, additional, Navale, Pooja, additional, Torres, Callie, additional, Su, Tung-Hung, additional, Graham, Rondell, additional, Salcedo, María, additional, Bermúdez, María, additional, Tran, Nguyen H., additional, Pawlotsky, Jean-Michel, additional, Verset, Gontran, additional, Trépo, Eric, additional, Varela, Maria, additional, Castano-Garcia, Andrés, additional, Wendum, Dominique, additional, Amaddeo, Giuliana, additional, Regnault, Helene, additional, Lequoy, Marie, additional, Díaz, Alba, additional, Reig, María, additional, Radu, Pompilia, additional, Dufour, Jean-François, additional, Chan, Stephen, additional, Gopal, Purva, additional, Bruges, Léa, additional, Gnemmi, Viviane, additional, Nault, Jean Charles, additional, Rhee, Hyungjin, additional, Park, Young Nyun, additional, Iñarrairaegui, Mercedes, additional, Argemi, Josep Maria, additional, Sangro, Bruno, additional, D’Alessio, Antonio, additional, Scheiner, Bernhard, additional, Pinato, David J., additional, Pinter, Matthias, additional, Paradis, Valérie, additional, Beaufrère, Aurélie, additional, Peter, Simon, additional, Rimassa, Lorenza, additional, Di Tommaso, Luca, additional, Vogel, Arndt, additional, Michalak, Sophie, additional, Boursier, Jerome, additional, Loménie, Nicolas, additional, Ziol, Marianne, additional, and Calderaro, Julien, additional

Published
2023
Full Text
View/download PDF

44. Survival outcomes from Atezolizumab plus Bevacizumab versus Lenvatinib versus Sorafenib in Child Pugh B unresectable hepatocellular carcinoma patients

Author

Rimini, Margherita, primary, Persano, Mara, additional, Tada, Toshifumi, additional, Suda, Goki, additional, Shigeo, Shimose, additional, Kudo, Masatoshi, additional, Cheon, Jaekyung, additional, Finkelmeier, Fabian, additional, Lim, Ho Yeong, additional, Presa, José, additional, Lonardi, Sara, additional, Piscaglia, Fabio, additional, Chon, Hong Jae, additional, Masi, Gianluca, additional, Scartozzi, Mario, additional, Cascinu, Stefano, additional, and Casadei-Gardini, Andrea, additional

Published
2023
Full Text
View/download PDF

45. Incidence and risk factors of esophagogastric varices bleeding in patients with advanced hepatocellular carcinoma treated with lenvatinib

Author

Iavarone, Massimo, primary, Alimenti, Eleonora, additional, Tada, Toshifumi, additional, Shigeo, Shimose, additional, Suda, Goki, additional, Yoo, Changhoon, additional, Soldà, Caterina, additional, Piscaglia, Fabio, additional, Gardini, Andrea Casadei, additional, Marra, Fabio, additional, Vivaldi, Caterina, additional, Conti, Fabio, additional, Schirripa, Marta, additional, Iwamoto, Hideki, additional, Sho, Takuya, additional, Leo, So Heun, additional, Rizzato, Mario Domenico, additional, Tonnini, Matteo, additional, Rimini, Margherita, additional, Campani, Claudia, additional, Masi, Gianluca, additional, Foschi, Francesco, additional, Bruccoleri, Mariangela, additional, Kawaguchi, Takumi, additional, Kumada, Takashi, additional, Hiraoka, Atsushi, additional, Atsukawa, Masanori, additional, Fukunishi, Shinya, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Kawata, Kazuhito, additional, Tada, Faujimasa, additional, Ohama, Hideko, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Arai, Taeang, additional, Imai, Michitaka, additional, Naganuma, Atsushi, additional, Tosetti, Giulia, additional, and Lampertico, Pietro, additional

Published
2023
Full Text
View/download PDF

46. Correction to: Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis

Author

Bang, Yeonghak, Yoo, Changhoon, Lonardi, Sara, Kim, Hyung-Don, Vivaldi, Caterina, Rimini, Margherita, Frassineti, Giovanni Luca, Park, Sook Ryun, Rizzato, Mario Domenico, Ryu, Min-Hee, Salani, Francesca, Rapposelli, Ilario Giovanni, Ryoo, Baek-Yeol, Zagonel, Vittorina, Massa, Valentina, Valgiusti, Martina, Burgio, Valentina, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2021
Full Text
View/download PDF

47. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study.

Author

Zeng, Qinghe, Klein, Christophe, Caruso, Stefano, Maille, Pascale, Allende, Daniela S, Mínguez, Beatriz, Iavarone, Massimo, Ningarhari, Massih, Casadei-Gardini, Andrea, Pedica, Federica, Rimini, Margherita, Perbellini, Riccardo, Boulagnon-Rombi, Camille, Heurgué, Alexandra, Maggioni, Marco, Trepo, Eric, Vij, Mukul, Baulande, Sylvain, Legoix, Patricia, Lameiras, Sonia, HCC-AI study group, Bruges, Léa, Gnemmi, Viviane, Nault, Jean Charles, Campani, Claudia, Rhee, Hyungjin, Park, Young Nyun, Iñarrairaegui, Mercedes, Garcia-Porrero, Guillermo, Argemi, Josepmaria, Sangro, Bruno, D'Alessio, Antonio, Scheiner, Bernhard, Pinato, David James, Pinter, Matthias, Paradis, Valérie, Beaufrère, Aurélie, Peter, Simon, Rimassa, Lorenza, Di Tommaso, Luca, Vogel, Arndt, Michalak, Sophie, Boursier, Jérôme, Loménie, Nicolas, Ziol, Marianne, Calderaro, Julien, Zeng, Qinghe, Klein, Christophe, Caruso, Stefano, Maille, Pascale, Allende, Daniela S, Mínguez, Beatriz, Iavarone, Massimo, Ningarhari, Massih, Casadei-Gardini, Andrea, Pedica, Federica, Rimini, Margherita, Perbellini, Riccardo, Boulagnon-Rombi, Camille, Heurgué, Alexandra, Maggioni, Marco, Trepo, Eric, Vij, Mukul, Baulande, Sylvain, Legoix, Patricia, Lameiras, Sonia, HCC-AI study group, Bruges, Léa, Gnemmi, Viviane, Nault, Jean Charles, Campani, Claudia, Rhee, Hyungjin, Park, Young Nyun, Iñarrairaegui, Mercedes, Garcia-Porrero, Guillermo, Argemi, Josepmaria, Sangro, Bruno, D'Alessio, Antonio, Scheiner, Bernhard, Pinato, David James, Pinter, Matthias, Paradis, Valérie, Beaufrère, Aurélie, Peter, Simon, Rimassa, Lorenza, Di Tommaso, Luca, Vogel, Arndt, Michalak, Sophie, Boursier, Jérôme, Loménie, Nicolas, Ziol, Marianne, and Calderaro, Julien

Abstract

Clinical benefits of atezolizumab plus bevacizumab (atezolizumab-bevacizumab) are observed only in a subset of patients with hepatocellular carcinoma and the development of biomarkers is needed to improve therapeutic strategies. The atezolizumab-bevacizumab response signature (ABRS), assessed by molecular biology profiling techniques, has been shown to be associated with progression-free survival after treatment initiation. The primary objective of our study was to develop an artificial intelligence (AI) model able to estimate ABRS expression directly from histological slides, and to evaluate if model predictions were associated with progression-free survival., info:eu-repo/semantics/published

Published
2023

48. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large, real-life, worldwide population.

Author

Rimini, Margherita, primary, Casadei-Gardini, Andrea, additional, Persano, Mara, additional, Tada, Toshifumi, additional, Suda, Goki, additional, Shimose, Shigeo, additional, Kudo, Masatoshi, additional, Cheon, Jaekyung, additional, Finkelmeier, Fabian, additional, Rimassa, Lorenza, additional, Presa, Josè, additional, Masi, Gianluca, additional, Yoo, Changhoon, additional, Lonardi, Sara, additional, Tovoli, Francesco, additional, Scartozzi, Mario, additional, Burgio, Valentina, additional, Cascinu, Stefano, additional, and Cucchetti, Alessandro, additional

Published
2023
Full Text
View/download PDF

49. Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab

Author

Rimini, Margherita, primary, Persano, Mara, additional, Tada, Toshifumi, additional, Suda, Goki, additional, Shimose, Shigeo, additional, Kudo, Masatoshi, additional, Cheon, Jaekyung, additional, Finkelmeier, Fabian, additional, Lim, Ho Yeong, additional, Presa Ramos, José, additional, Masi, Gianluca, additional, Yoo, Changhoon, additional, Lonardi, Sara, additional, Stefanini, Bernardo, additional, Kumada, Takashi, additional, Sakamoto, Naoya, additional, Iwamoto, Hideki, additional, Aoki, Tomoko, additional, Chon, Hong Jae, additional, Himmelsbach, Vera, additional, Montes, Margarida, additional, Vivaldi, Caterina, additional, Soldà, Caterina, additional, Hiraoka, Atsushi, additional, Sho, Takuya, additional, Niizeki, Takashi, additional, Nishida, Naoshi, additional, Steup, Christoph, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Tani, Joji, additional, Atsukawa, Masanori, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Tsuji, Kunihiko, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Ogawa, Chikara, additional, Nishimura, Takashi, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Shimada, Noritomo, additional, Kawata, Kazuhito, additional, Tada, Fujimasa, additional, Ohama, Hideko, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Arai, Taeang, additional, Imai, Michitaka, additional, Kosaka, Hisashi, additional, Naganuma, Atsushi, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Kaibori, Masaki, additional, Iijima, Hiroko, additional, Hiasa, Yoichi, additional, Burgio, Valentina, additional, Della Corte, Angelo, additional, Ratti, Francesca, additional, De Cobelli, Francesco, additional, Aldrighetti, Luca, additional, Scartozzi, Mario, additional, Cascinu, Stefano, additional, and Casadei-Gardini, Andrea, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results